Depression affects nearly 350 million people worldwide, but long waiting lines and limited access to services have impeded depression treatment. Only about a quarter of patients in the United States have received any type of psychological therapy in the last year and 1 in 10 UK citizens have been waiting over a year to receive treatment.
Depression affects nearly 350 million people worldwide, but long waiting lines and limited access to services have impeded depression treatment. Only about a quarter of patients in the United States have received any type of psychological therapy in the last year and 1 in 10 UK citizens have been waiting over a year to receive treatment. However, new research published in The Lancet found that behavioral activation (BA), a talking therapy, is as effective as the traditional cognitive behavioral therapy (CBT) and can be delivered at far less of a cost.
CBT has long been the gold standard for psychological therapy among patients with depression, in which the treatment takes an “inside out” approach that focuses on the way the individual thinks. Under this treatment, therapists help their patients understand how he or she thinks about themselves and the world around them as well as encourages them to modify negative beliefs, said lead study author David Richards, Professor of Mental Health Services Research at the University of Exeter, UK.
On the other hand, BA therapy is a much simpler and newer therapy that takes the opposite approach, an “outside in” tactic, when treating the patient. Richards explained that BA therapy helps patients change the way they act by helping them to better link their behavior to their moods and encourages individuals to seek more positive experiences.
Richards and his research team completed one of the largest study’s regarding psychological treatment for depression and discovered that BA therapy not only produced similar outcomes to that of CBT, but could also be delivered by non-specialist staff, which leads to lower costs and greater accessibility.
The trial recruited about 440 adults with depression from primary care and psychological therapy services from 3 specific areas in England. Researchers randomly divided study participants in half, the first receiving BA therapy from junior mental health workers and the later receiving CBT by experienced psychological therapists, as CBT can only be delivered by specialist clinicians and therapists who are expensive to both train and employ.
The study found that two-thirds of both study groups reported at least a 50% decrease in depression symptoms and reported similar numbers for depression-free days and anxiety diagnoses. Researchers suggested that the outcomes found among those who underwent BA therapy were no worse than the outcomes obtained in patients receiving CBT.
"Our findings challenge the dominance of CBT as the leading evidence-based psychological therapy for depression", said Richards in a statement. "Behavioral activation should be a front-line treatment for depression in the UK and has enormous potential to improve reach and access to psychological therapy worldwide."
The researchers added that the study’s findings have substantial implications on the accessibility to psychological therapy and the greater ease with which a BA workforce could be trained in the future. While CBT has been the dominant therapy option for years, the authors wrote that this study’s findings have great potential to challenge the future of depression treatment across the globe.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More